Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.28) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.
Brainstorm Cell Therapeutics Trading Down 2.7%
Shares of NASDAQ:BCLI opened at $0.67 on Thursday. The company has a fifty day simple moving average of $0.80 and a 200 day simple moving average of $0.67. The firm has a market cap of $7.39 million, a PE ratio of -0.20 and a beta of 0.22. Brainstorm Cell Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.92.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
See Also
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
